Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Left ventricular assist device (LVAD) therapy has been the standard of care for selected patients with advance heart failure. Even though considerable strides have been achieved with the introduction of the newest centrifugal pump, therapy is still burdened with significant perioperative complications. Smaller devices, along with improved techniques and instruments, have encouraged the adoption of minimally invasive cardiac surgery (MICS) techniques for LVAD implantation to improve perioperative outcomes.
Methods: We describe a technique for complete sternal-sparing (CSS) HeartMate 3 (Abbott Laboratories, Abbott Park, IL) left ventricular assist device (LVAD) implantation using bilateral thoracotomies and discuss early clinical outcomes of the first ten consecutive patients who underwent CSS implantation of the HeartMate 3 LVAD at our institution.
Results: The median length of stay in the intensive care unit was 3.5 days. No patients required reexploration for postoperative bleeding. There was no incidence of right ventricle failure, stroke, renal failure, hepatic failure, or myocardial infarction. The median length of hospitalization after LVAD implantation was 14.5 days (interquartile range, 12 to 17 days).
Conclusions: Our early outcomes suggest that the CSS approach may reduce the incidence of right ventricular failure, bleeding, intubation time, and intensive care unit length of stay. Further studies are needed to fully elucidate the advantages of CSS LVAD implantation compared with median sternotomy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.athoracsur.2018.10.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
One-stage surgical management for advanced dilated cardiomyopathy combined with aortic sinus aneurysm: a case report.
Front Cardiovasc Med
August 2025
Department of Cardiovascular Surgery, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Introduction: Left ventricular assist device (LVAD) implantation is a highly effective procedure for the management of selected advanced heart failure patients, prolonging patient life and improving quality. Additional cardiac pathologies, especially valvular regurgitation or coronary heart disease, are common in LVAD recipients, whereas reports on the surgical management of heart failure combined with aortic disease are rare.
Case Presentation: We present a case of a 60-year-old patient with an aortic sinus aneurysm, aortic regurgitation, and end-stage heart failure.
Long Term Outcomes of Tricuspid Valve Repair or Replacement in Patients with Continuous Flow Left Ventricular Assist Devices.
J Thorac Cardiovasc Surg
September 2025
Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, NY. Electronic address:
Objective: Our objective was to determine the long-term outcomes of concomitant tricuspid valve procedures (TVP) during continuous-flow left ventricular assist device (LVAD) implantation.
Methods: We retrospectively reviewed patients who received HeartMate II or 3 from 2004 to 2023. Nine patients who had a previous TVP were excluded.
Safe Practices: Partial Coverage of Left Ventricular Assist Device Reduces Bleeding Risk during Explant-Heart Transplant without Causing Obstruction.
J Heart Lung Transplant
September 2025
Vanderbilt University Medical Center, Department of Cardiac Surgery, Nashville, TN. Electronic address:
Left ventricular assist device (LVAD) explantation is technically challenging during heart transplantation (HT) and is associated with intraoperative and postoperative blood loss. This single institution study examined the effects of partial polytetrafluoroethylene (PTFE) protective coverage during HeartMate 3 implant on perioperative blood loss during the explant-HT. We found that partial PTFE coverage of the outflow graft and chassis during HeartMate 3 implant is significantly associated with reduced intraoperative and postoperative transfusion requirements, and postoperative chest tube output.
View Article and Find Full Text PDFStrategic Approach Towards the Evaluation of HeartMate 3 Left Ventricular Assist Devices Using Multimodality Imaging.
Am J Cardiol
August 2025
Division of Cardiovascular Diseases and Hypertension, Rutgers University - Robert Wood Johnson Medical School, 125 Paterson Street, East Tower - 8th Floor, New Brunswick, New Jersey 08901, United States. Electronic address:
The use of left ventricular assist devices (LVADs) has increased in recent years as a destination therapy. The HeartMate 3 (HM3) is currently the only commercially available LVAD for implantation in the United States. Societal guidelines for multimodality cardiac imaging evaluation of LVADs and temporary mechanical support devices were recently published and serve as a comprehensive resource for the evaluation of LVAD patients.
View Article and Find Full Text PDFImpact of pump position on postoperative outcomes in less invasive left ventricular assist device implantation.
Front Cardiovasc Med
August 2025
Department of Cardiac Surgery and Research Group for Experimental Surgery, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany.
Introduction: less invasive approach (LIS) has recently become increasingly used for left ventricular assist device (LVAD) implantation. However, the impact of surgical access on pump position and clinical outcomes comparing LIS-LVAD implantation to full sternotomy (ST) has not been well discussed.
Methods: Between April 2010 and February 2021, a total of 237 consecutive patients received a LVAD, 76 (32.